3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Lung Neoplasms
4
Head and Neck Neoplasms
4
Glioblastoma
4
Breast Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Glioma
3
Brain Neoplasms
3
Virus Diseases
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Neoplasms
2
Melanoma
2
Liver Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Pharyngeal Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Nose Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Interventions
Magnetic Resonance Spectroscopy
6
Dexamethasone
6
Cyclophosphamide
6
Blood Specimen Collection
6
Prednisone
5
Positron Emission Tomography Computed Tomography
4
Mammography
4
Lenalidomide
4
Colonoscopy
4
pembrolizumab
3
Tomography, X-Ray Computed
3
Surveys and Questionnaires
3
Melphalan
3
Exercise
3
Biopsy
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
weifuchun
2
obinutuzumab
2
fluciclovine F-18
2
daratumumab
2
carfilzomib
2
Preoperative Exercise
2
Positron-Emission Tomography
2
Methods
2
Magnetic Resonance Imaging
2
Injections
2
Gemcitabine
2
Educational Status
2
Doxorubicin
2
Cytarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Disease
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled